Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rayner
Worthing, West Sussex, United Kingdom
- Ownership
- Private
- Employees
- ~417
- Development stage
- Other
01
Overview
Rayner develops and markets a full suite of commercial ophthalmic devices and products for cataract surgery and ocular disease, with products including intraocular lenses (IOLs), ophthalmic viscosurgical devices (OVDs), the OMIDRIA® (phenylephrine and ketorolac) solution for cataract surgery, and digital outcomes platforms[1][3][4].
- Therapeutic areas
- Ophthalmology
- Modalities
- DeviceSmall moleculeBiologic
- Industry
- Implantable Medical Devices
02
Partnerships
Omeros Corporation (for OMIDRIA acquisition)
Beyond the preview
Go deeper on Rayner.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rayner.